de Verneuil Vanina 4
4 · Vir Biotechnology, Inc. · Filed Feb 25, 2025
Insider Transaction Report
Form 4
de Verneuil Vanina
EVP, General Counsel, Corp Sec
Transactions
- Award
Common Stock
2025-02-22+35,000→ 91,973 total - Sale
Common Stock
2025-02-24$9.45/sh−5,140$48,590→ 86,833 total - Award
Stock Option (Right to Buy)
2025-02-22+70,000→ 70,000 totalExercise: $9.57Exp: 2035-02-21→ Common Stock (70,000 underlying)
Footnotes (3)
- [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
- [F2]Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
- [F3]25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter.